Editas Medicine, Inc. announced the appointment of Caren Deardorf as the Company?s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine?s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company?s current and future pipeline of products. Caren Deardorf brings to Editas more than 25 years of international biotechnology leadership across a range of companies and therapeutic areas.

Most recently, Ms. Deardorf served as the Chief Commercial Officer of Magenta Therapeutics. Prior to Magenta, she served as the Chief Commercial Officer of Ohana Biosciences where she was responsible for developing a commercial strategy, including planning for the company?s first product launch. Earlier in her career, Ms. Deardorf held a variety of commercial roles of increasing responsibility at Biogen, most recently serving as Vice President, Product Development & Commercialization, leading and executing a highly successful global launch of SPINRAZA, a treatment for children and adults with spinal muscular atrophy.

During her tenure at Biogen, Ms. Deardorf was instrumental in building the multiple sclerosis (MS) franchise and helping to establish Biogen?s global leadership through US and worldwide brand management, including leading the brand and launch strategy for TECFIDERA and the successful US and EU launches of TYSABRI and AVONEX. Ms. Deardorf holds a Bachelor of Science degree in biology from Tufts University and a Master of Business Administration from the Olin Graduate School of Business at Babson College. Ms. Deardorf serves on the Boards of Directors for Crinetics Pharmaceuticals and for NeuroSense Therapeutics.

She is also a board member for the Pan-Mass Challenge, a non-profit organization that raises funds for Dana-Farber Center Institute.